Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 61 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
CYTIVA BELGIUM from Hoegaarden, company number BE0783590249, closed financial year 2025 with a result of € 18.9 million after tax. For that financial year CYTIVA BELGIUM recorded revenue of € 1.2 billion and equity of € 12.4 million. Compared with financial year 2024, the result moved from € 26.5 million to € 18.9 million. The company is profitable. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 18, 2026.
€ 12.4 million
▼ 25% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 18.9 million
▼ 29% vs 2024
Profit after tax over the fiscal year.
€ 23 million paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
93.6
▲ 7.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 15.4 million
▲ 21% vs 2024
€ 164,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 55.5 million
▲ 99% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 18 days on average.
€ 7.4 million
▲ 159% vs 2024
Taxes, VAT and social contributions still to pay.
| 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|
| Revenue | € 419,054,850 | € 1,141,150,938 | € 1,183,869,278 | ▲ 4% |
| Profit after taxes | € 15,088,554 | € 26,547,075 | € 18,919,560 | ▼ 29% |
| Equity | € 14,909,070 | € 16,456,145 | € 12,375,706 | ▼ 25% |
| Total debts | € 168,674,847 | € 98,335,199 | € 141,164,321 | ▲ 44% |
| Cash | € 63,712,776 | - | - | |
| Retained profit | € 3,088,554 | € 4,635,629 | € 555,190 | ▼ 88% |
| Dividend | € 12,000,000 | € 25,000,000 | € 23,000,000 | ▼ 8% |
| Balance sheet total | € 183,754,129 | € 114,995,241 | € 153,679,614 | ▲ 34% |
| Employees (FTE) | 82.3 | 86.3 | 93.6 | ▲ 7.3 |
Key figures of CYTIVA BELGIUM, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CYTIVA BELGIUM?
What happened at CYTIVA BELGIUM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 18.9 million (▼ 29% vs 2024). Source: NBB ↗
- Sylvia Steenwinckel became a director. NBB
- Steven Vanhamel became a director. NBB
- Bernard Goethals became a director. NBB
- New establishment in Hoegaarden. KBO
- Start of the company according to the CBE. KBO
In short
From € 15.1 million profit in 2023 to € 18.9 million profit in 2025.
Paid € 20.7 million in corporate taxes since 2023.
Best year ever: 2024, with € 26.5 million profit.
Paid out € 60 million in dividends to the owners in total.
Management
Behind CYTIVA BELGIUM are Bernard Goethals, Sylvia Steenwinckel and Steven Vanhamel. The shares are held by Pall Life Sciences Belgium (100%).
Directors
According to the 2025 annual accounts
since 2023
since 2024
since 2023
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Reugelstraat 2
3320 Hoegaarden
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0783.590.249
- VAT number
- BE 0783.590.249
- Registered office
- Reugelstraat 2, 3320 Hoegaarden
- Names & denominations
- CYTIVA BELGIUM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 18 March 2022
- Peppol
- Active · Active since 23 Jan 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Activiteiten van medische beeldvorming en medische laboratoria
Activiteiten van medische laboratoria
Overige bouwinstallatie
Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg
Overige technische testen en toetsen
Vervaardiging van farmaceutische grondstoffen
Overige bouwinstallatie, n.e.g.
+1